Vanderbilt University Medical Center: Study Reports Final Clinical Trial Data for Advanced Kidney Cancer Treatment
August 02, 2025
August 02, 2025
NASHVILLE, Tennessee, Aug. 2 (TNSjou) -- Vanderbilt University Medical Center issued the following news release:
* * *
Study reports final clinical trial data for advanced kidney cancer treatment
The drug combo pembrolizumab plus axitinib had sustained and durable clinical benefit in more than five years of follow-up. It is a standard-of-care first-line treatment for advanced kidney cancer.
*
A two-drug combination for treating adv . . .
* * *
Study reports final clinical trial data for advanced kidney cancer treatment
The drug combo pembrolizumab plus axitinib had sustained and durable clinical benefit in more than five years of follow-up. It is a standard-of-care first-line treatment for advanced kidney cancer.
*
A two-drug combination for treating adv . . .